6YG Stock Chart & Stats
€30.40
-€0.60(-1.94%)
At close: 4:00 PM EDT
€30.40
-€0.60(-1.94%)
Day’s Range― - ―
52-Week Range€23.20 - €35.60
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€1.49B
Enterprise Value€1.19K
Total Cash (Recent Filing)€880.21M
Total Debt (Recent Filing)€434.96M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Nov 11, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding50,865,574
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)4.59
Price to Sales (P/S)5.87
P/FCF Ratio-156.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€56.76Price Target Upside86.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.13
Revenue Forecast (FY)€388.29M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Scale And Very High Gross MarginsRevenue has scaled materially to $403.7M TTM while product-level gross margins remain exceptionally high (~96%–100%). This combination creates durable product economics, enabling operating leverage as sales grow and supporting sustainable margin expansion over the next several quarters to years.
Commercial Product With Supportive Long-term Clinical DataFive-year survival data and near-complete Phase 3 enrollment materially de-risk commercial adoption and reimbursement for KIMMTRAK. Durable clinical benefit strengthens physician uptake and payer negotiations, and validates commercial scale that can underpin multi-year revenue visibility and platform credibility.
Proprietary ImmTAC Platform And Collaborative Revenue StreamsA proprietary TCR‑based ImmTAC platform is a structural competitive advantage, enabling multiple indication expansion and partner collaborations. Platform-driven partnerships and milestone/royalty mechanics can diversify long-term revenue beyond the lead product as programs advance.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicates ongoing cash burn while commercial investment continues. This reduces the company's ability to self-fund growth, increases reliance on external financing, and raises execution risk if capital markets tighten or milestone timing slips over the next several quarters.
Elevated Leverage And Constrained Balance Sheet FlexibilityLeverage above 1.0 alongside ongoing losses limits financial flexibility, increasing interest and refinancing risk. Elevated debt amplifies downside if revenue growth slows and constrains capacity to invest in commercial expansion or late‑stage trials without additional capital raises or deleveraging.
Concentration On KIMMTRAK & Milestone Timing ExposureRevenue is primarily tied to one marketed therapy, with other income dependent on partner milestones and timing. This concentration exposes cash flow to demand, reimbursement, and regulatory risks for KIMMTRAK and to unpredictable milestone schedules for partnered programs, increasing medium‑term revenue volatility.
Immunocore Holdings News
6YG FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was €23.20 and its highest was €35.60 in the past 12 months.
What is Immunocore Holdings’s market cap?
Immunocore Holdings’s market cap is €1.49B.
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is Nov 11, 2026 which is in 96 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Aug 06, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of €0.009 by -€0.026.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -0.11.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 50,865,574 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of -€0.017 in its last earnings report, missing expectations of €0.009. Following the earnings report the stock price went up 2.098%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Currently, no hedge funds are holding shares in DE:6YG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunocore Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€56.76 (86.71% Upside)
€56.76 (86.71% Upside)
Blogger Sentiment
Bullish
DE:6YG Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.29%
Trailing 12-Months
Company Description
Immunocore Holdings
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
6YG Company Deck
6YG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial execution for KIMTRAK (29% YoY revenue growth to $400M), broad global adoption (39 approvals, 30 launches), meaningful real-world survival and duration signals, a diversified pipeline anchored by three Phase 3 trials with near-term readouts, and a solid cash position (~$864M). Balanced against this are expected revenue-growth moderation in 2026, rising R&D investment, event-driven timing uncertainty for key OS trials, small early-stage cohorts (HIV), and competitive/operational risks tied to trial geography and evolving treatment options. Overall, the company presents momentum and optionality but with important clinical and timing risks that will be clarified by upcoming data readouts.View all DE:6YG earnings summaries6YG Stock 12 Month Forecast
Average Price Target
€56.76
▲(86.71% Upside)